CD8A and myeloid leukemia: To further study any issues that impeded the efficacy of the combination of PD-L1 blockade with PLK1122DC_TriVax in myeloid leukaemia setting, we initially assessed for the presence of antigen-specific CD8 T-cells after euthanatising three mice in each group after 23-days of tumour infusion.